No single score captures the burden of treatment in people with cystic fibrosis (pwCF), according to systematic review study findings published in the Journal of Cystic Fibrosis.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Lupin receives USFDA approval for its generic version of Ivacaftor oral granules, a treatment for cystic fibrosis. The ...

India has the potential to increase exports of organic products up to Rs 20,000 crore in the next three years, Commerce and ...

Scientists at Caltech and Princeton University have discovered that bacterial cells growing in a solution of polymers, such ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals. The FDA has approved ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...

It is their job to stay up to date on the latest cystic fibrosis treatment guidelines and new medications and therapies. They often work in specialized cystic fibrosis centers and collaborate with ...

(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...

Ivacaftor oral granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for the treatment of cystic fibrosis (CF) in patients aged four months and older who have at least one mutation in ...